These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
33. Bortezomib abolishes tumor necrosis factor-related apoptosis-inducing ligand resistance via a p21-dependent mechanism in human bladder and prostate cancer cells. Lashinger LM; Zhu K; Williams SA; Shrader M; Dinney CP; McConkey DJ Cancer Res; 2005 Jun; 65(11):4902-8. PubMed ID: 15930312 [TBL] [Abstract][Full Text] [Related]
34. Proteasome inhibitor Bortezomib induces cell cycle arrest and apoptosis in cell lines derived from Ewing's sarcoma family of tumors and synergizes with TRAIL. Lu G; Punj V; Chaudhary PM Cancer Biol Ther; 2008 Apr; 7(4):603-8. PubMed ID: 18223318 [TBL] [Abstract][Full Text] [Related]
35. In vivo gene delivery by embryonic-stem-cell-derived astrocytes for malignant gliomas. Uzzaman M; Keller G; Germano IM Neuro Oncol; 2009 Apr; 11(2):102-8. PubMed ID: 18676359 [TBL] [Abstract][Full Text] [Related]
36. Cooperative cytotoxicity of proteasome inhibitors and tumor necrosis factor-related apoptosis-inducing ligand in chemoresistant Bcl-2-overexpressing cells. Nencioni A; Wille L; Dal Bello G; Boy D; Cirmena G; Wesselborg S; Belka C; Brossart P; Patrone F; Ballestrero A Clin Cancer Res; 2005 Jun; 11(11):4259-65. PubMed ID: 15930365 [TBL] [Abstract][Full Text] [Related]
37. A comparative study of neural and mesenchymal stem cell-based carriers for oncolytic adenovirus in a model of malignant glioma. Ahmed AU; Tyler MA; Thaci B; Alexiades NG; Han Y; Ulasov IV; Lesniak MS Mol Pharm; 2011 Oct; 8(5):1559-72. PubMed ID: 21718006 [TBL] [Abstract][Full Text] [Related]
38. The proteasome inhibitor bortezomib disrupts tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression and natural killer (NK) cell killing of TRAIL receptor-positive multiple myeloma cells. Feng X; Yan J; Wang Y; Zierath JR; Nordenskjöld M; Henter JI; Fadeel B; Zheng C Mol Immunol; 2010 Aug; 47(14):2388-96. PubMed ID: 20542572 [TBL] [Abstract][Full Text] [Related]
39. The application of mRNA-based gene transfer in mesenchymal stem cell-mediated cytotoxicity of glioma cells. Guo XR; Yang ZS; Tang XJ; Zou DD; Gui H; Wang XL; Ma SN; Yuan YH; Fang J; Wang B; Zhang L; Sun XY; Warnock GL; Dai LJ; Tu HJ Oncotarget; 2016 Aug; 7(34):55529-55542. PubMed ID: 27487125 [TBL] [Abstract][Full Text] [Related]
40. Tumoricidal stem cell therapy enables killing in novel hybrid models of heterogeneous glioblastoma. Satterlee AB; Dunn DE; Lo DC; Khagi S; Hingtgen S Neuro Oncol; 2019 Dec; 21(12):1552-1564. PubMed ID: 31420675 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]